[Clinical progress of vasopressin in the treatment of septic shock]

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Apr;31(4):501-504. doi: 10.3760/cma.j.issn.2095-4352.2019.04.027.
[Article in Chinese]

Abstract

Septic shock is a serious stage of sepsis with a hospital mortality rate of more than 40%. The pathophysiology of septic shock is vasodilation and increased permeability. Fluid resuscitation, vasopressor drugs are usually used to maintain the perfusion pressure of the main organs. However, infectious patients usually have the irresponsive vessel to catecholamines and may lead to obvious side effects using high doses of norepinephrine or dopamine. Recent studies have shown that vasopressin (AVP) improves hemodynamics, increases tissue perfusion, and synergizes with norepinephrine in patients with septic shock, showing extent application prospects in the treatment of septic shock. The practice of AVP in septic shock is reviewed in this article in order to provide a reference for clinicians.

Publication types

  • Review

MeSH terms

  • Humans
  • Shock, Septic / drug therapy*
  • Treatment Outcome
  • Vasopressins / therapeutic use*

Substances

  • Vasopressins